{"corpus_id":235687046,"paper_sha":"76dabac7c62e8e57277026c9310c714aba98c705","doi":"10.1111/eip.13182","arxiv_id":null,"pmid":34190422,"pmcid":null,"mag_id":null,"dblp_id":null,"acl_id":null,"title":"Cannabidiol for at risk for psychosis youth: A randomized controlled trial","year":2021,"publication_date":"2021-06-30","venue":"Early Intervention in Psychiatry","journal":{"name":"Early Intervention in Psychiatry","pages":"419 - 432","volume":"16"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine","Psychology"],"reference_count":99,"citation_count":12,"influential_citation_count":0,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Administration, Oral","mj":false,"ui":"D000284"},{"d":"Adolescent","mj":false,"ui":"D000293"},{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Cannabidiol","mj":true,"qs":[{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D002185"},{"d":"Child","mj":false,"ui":"D002648"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Psychotic Disorders","mj":true,"qs":[{"q":"diagnosis","mj":false,"ui":"Q000175"}],"ui":"D011618"},{"d":"Young Adult","mj":false,"ui":"D055815"}],"chemicals":[{"n":"Cannabidiol","ui":"D002185","reg":"19GBJ60SN5"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"http://minerva-access.unimelb.edu.au/bitstreams/9e11a16d-df9a-555d-8a8c-102d4104463c/download","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/76dabac7c62e8e57277026c9310c714aba98c705","s2_open_access_license":"mit","s2_open_access_status":"GREEN","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"No biological treatment has been firmly established for the at‐risk stage of psychotic disorder. In this study we aim to test if subthreshold psychotic symptoms can be effectively treated with cannabidiol (CBD), a non‐psychoactive compound of the plant Cannabis sativa. The question has taken on increased importance in the wake of evidence questioning both the need and efficacy of specific pharmacological interventions in the ultra‐high risk (UHR) for psychosis group.","claims":[{"public_id":"cl_a93e73d174241d3ac5a9b27ef0c19546","status":"active","text":"Cannabidiol is being tested as a treatment for subthreshold psychotic symptoms in youth at ultra-high risk for psychosis.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_a93e73d174241d3ac5a9b27ef0c19546"},{"public_id":"cl_9f93fba9345bde41f0d8af133026ad09","status":"active","text":"The randomized controlled trial targets the at-risk stage of psychotic disorder, where no biological treatment has been firmly established.","confidence":0.87,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_9f93fba9345bde41f0d8af133026ad09"}],"concepts":[{"public_id":"co_1171a665e120247672db101715a7d51b","status":"active","name":"subthreshold psychotic symptoms","description":"Psychotic-like symptoms that do not meet the threshold for a full psychotic disorder.","types":["symptom"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1171a665e120247672db101715a7d51b"},{"public_id":"co_478583188a5cc5ca0d57baa5e11f6f5b","status":"active","name":"biological treatment","description":"A pharmacological or other biologically based intervention used to treat illness.","types":["treatment"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_478583188a5cc5ca0d57baa5e11f6f5b"},{"public_id":"co_5567d345bd38a66c95459fbff2ac12ed","status":"active","name":"at-risk stage of psychotic disorder","description":"The prodromal or high-risk phase before a diagnosable psychotic disorder emerges.","types":["clinical stage"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5567d345bd38a66c95459fbff2ac12ed"},{"public_id":"co_5a5e48add76c5ffa421dcf0ac87b0b82","status":"active","name":"cannabidiol","description":"A non-psychoactive compound derived from the plant Cannabis sativa.","types":["compound","treatment candidate"],"aliases":["CBD"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5a5e48add76c5ffa421dcf0ac87b0b82"},{"public_id":"co_7c49536e75f17b411d8c02c675f27be6","status":"active","name":"Cannabis sativa","description":"The plant species from which cannabidiol is obtained.","types":["plant"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7c49536e75f17b411d8c02c675f27be6"},{"public_id":"co_993da3193de03756a06e5024f2b3c4b1","status":"active","name":"psychotic disorder","description":"A psychiatric disorder characterized by impaired reality testing, such as hallucinations or delusions.","types":["disorder"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_993da3193de03756a06e5024f2b3c4b1"},{"public_id":"co_ad93e9fa4b54dbffb5501ae3c3b6cfc0","status":"active","name":"pharmacological interventions","description":"Drug-based treatments used to prevent or reduce symptoms or disease progression.","types":["treatment"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ad93e9fa4b54dbffb5501ae3c3b6cfc0"},{"public_id":"co_aee05b611754f3128685d67c4584cc1b","status":"active","name":"ultra-high risk for psychosis","description":"A clinical risk state in which a person has a high likelihood of developing psychosis.","types":["risk group"],"aliases":["UHR"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_aee05b611754f3128685d67c4584cc1b"},{"public_id":"co_fb2366f007da2bc5e000644ec11d5e02","status":"active","name":"randomized controlled trial","description":"An experimental study design that assigns participants to treatment conditions by random allocation.","types":["study design"],"aliases":["RCT"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_fb2366f007da2bc5e000644ec11d5e02"}],"external_ids":{"DOI":"10.1111/eip.13182","ArXiv":null,"PubMed":34190422,"PubMedCentral":null,"MAG":null,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"http://minerva-access.unimelb.edu.au/bitstreams/9e11a16d-df9a-555d-8a8c-102d4104463c/download","landing_url":"https://www.semanticscholar.org/paper/76dabac7c62e8e57277026c9310c714aba98c705","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"mit","status":"GREEN","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":634898,"paper_uid":"7a1f92a6-bc66-45ab-94c2-d55aeb542471","canonical_identity":{"paper_id":634898,"paper_uid":"7a1f92a6-bc66-45ab-94c2-d55aeb542471","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/235687046"}